Heineken, one of the world’s largest beer producers, has warned that the growing use of weight-loss medications such as Ozempic could pose a challenge to beer sales as some users report losing interest in alcohol.

The drugs, known as GLP-1 receptor agonists, were initially developed to treat Type 2 diabetes, but several have become widely used for weight management. They work by affecting appetite and feelings of fullness, helping patients eat less. Some users have also reported reduced cravings for alcohol, raising questions about how the medications could affect drinking habits and the wider beverage market.

For beer companies, the potential shift comes as the industry faces changing consumer preferences, pressure on household spending and growing interest in lower-alcohol alternatives. If people taking weight-loss medications drink less frequently or consume fewer alcoholic beverages, breweries could face another challenge in maintaining sales.

Heineken sells major international brands, including Heineken, Amstel and Birra Moretti, and operates in markets around the world. Any sustained change in alcohol consumption could affect demand across its portfolio, although the extent of the impact would depend on how widely the medications are used and whether changes in drinking habits persist over time.

The concern is not limited to beer consumption at home. Heineken also warned that traditional pub visits involving multiple pints could become less common as customers change their drinking habits. The company recommended that British pubs and bars offer half-pints, low- and no-alcohol beverages, and small plates of food to encourage customers to continue visiting while potentially spending less on alcohol.

live+1

Early consumer-spending data suggest the shift may already be underway. Research firm Circana tracked U.S. households between 2024 and 2026 and found that households with at least one GLP-1 medication user spent about 7% less per month on alcohol after two years than households without a user. Spending on beer was approximately 13.5% lower.

live+1

Interviews and surveys have also indicated that some users drink less because alcohol makes them feel uncomfortable or unwell, while others report a reduced desire to consume it. Researchers are investigating whether GLP-1 medications affect the brain's reward pathways in ways that reduce alcohol cravings, although the long-term effects across the wider population remain uncertain.

live+1

The potential impact extends beyond Heineken. The alcohol industry has already faced pressure in several major markets as consumers cut back for health and financial reasons. However, competitors have expressed differing views about the threat posed by weight-loss medications. Diageo has described the potential impact as manageable, while Carlsberg has said available data do not establish the drugs as a clear driver of beer consumption trends.

live+1

Heineken said it would continue monitoring changes in consumer behavior through 2027. The company also noted that people using GLP-1 medications were not necessarily abandoning alcohol altogether, with some shifting toward smaller servings, lower-alcohol beverages and more premium products.

The coming years will help determine whether the growing use of weight-loss medications produces a lasting change in alcohol consumption. For brewers and hospitality businesses, the challenge will be adapting to customers who may be eating less, drinking less, and choosing different products than they did before.